Akebia <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Expands Vafseo Availability Nationwide Across IRC Dialysis Clinics
Akebia Therapeutics, Inc., a biopharmaceutical company focused on improving the lives of those affected by kidney disease, and Innovative Renal Care (IRC) have announced the nationwide availability of Vafseo® (vadadustat) across all IRC dialysis clinics. This collaboration marks a significant step in expanding access to Vafseo, an innovative treatment for anemia due to chronic kidney disease (CKD) in dialysis patients. Implemented through IRC's extensive network of over 230 dialysis centers across 28 states and Washington, D.C., the treatment is now available for patients meeting FDA-approved criteria. This partnership is expected to significantly increase the adoption of Vafseo, which has been accessible to over 55,000 patients and aims to reach more than 275,000 by the end of Q4.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9515883-en) on August 21, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。